Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-2808 in Relapsed or Refractory Multiple Myeloma
NCT07116616Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Sep 2025
- Primary completion
- Jun 2030
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mRNA-2808 in multiple myeloma (MM), sponsored by Moderna Inc. Primary endpoints: Dose-limiting Toxicity at 28 days and Treatment-emergent Adverse Events at 15 months. Started Sep 2025; status: recruiting.
02
Drugs
mRNA-2808
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07116616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116616.